Actelion emphasizes commitment to advance research and care in rare diseases...
(Source: Actelion Ltd) 'Patient Voice - Join us in making the voice of rare diseases heard.' This is the theme of Rare Disease Day 2016 - and a cause for Actelion to emphasize its long-term commitment...
View ArticleActelion delivers outstanding 2014 results (Actelion Ltd)
(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 16 February 2015- Actelion Ltd (SIX: ATLN) today announced its results for the full year 2014. OPERATING HIGHLIGHTS Opsumit - Sales of CHF 180...
View ArticleActelion obtains "Epoprostenol ACT" label extension for pediatric PAH...
ALLSCHWIL, SWITZERLAND - 02 March 2017 - Actelion (SIX: ATLN) announced today that Japan's Ministry of Health, Labor and Welfare granted a label extension for dosage and administration for...
View ArticlePositive Phase II top-line results of Lorediplon (Ergomed plc)
(Source: Ergomed plc) PRESS RELEASE FOR IMMEDIATE RELEASE Ergomed announces positive Phase II top-line results of co-development partner Ferrer's Lorediplon for the treatment of insomnia London, UK - 6...
View ArticleACT-541468 (DORA) meets primary endpoint in Phase 2 program in adult and...
Allschwil, Switzerland - 28 July 2017 - Idorsia Ltd (SIX: IDIA) today announced positive results for the comprehensive Phase 2 program with the dual orexin receptor antagonist ACT-541468 (DORA) in...
View ArticleEisai and Purdue Pharma Enter Worldwide Collaboration to Develop and...
WOODCLIFF LAKE, N.J. and STAMFORD, Conn., Aug. 31, 2015 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., and Purdue Pharma L.P. announced today that they have entered...
View ArticleErgomed announces positive Phase II top-line results of co-development...
(Source: Ergomed plc) London, UK - 6 Febuary 2017: Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Company'), a company dedicated to the provision of specialised services to the pharmaceutical industry and...
View ArticleActelion is granted marketing authorization for Uptravi (selexipag) in...
(Source: Nippon Shinyaku Co Ltd) May 17. 2016 ・Marketing authorization granted by European Commission on 12 May 2016 ・First European Union (EU) market introduction to commence in the near future...
View ArticleEISAI INITIATES PHASE 2 CLINICAL TRIAL TO EVALUATE LEMBOREXANT IN THE...
(Source: Purdue Pharma LP) WOODCLIFF LAKE, N.J., and STAMFORD, Conn, Oct. 31, 2016 - Eisai and Purdue Pharma L.P. announced today the initiation of a multi-center, randomized Phase 2 clinical study...
View ArticleActelion provides an update on the Phase III IMPACT program with cadazolid in...
ALLSCHWIL, SWITZERLAND - 08 June 2017 - Actelion Ltd (SIX: ATLN) today provided an update on the Phase III program IMPACT to investigate the efficacy and safety of Actelion's novel anti-infective...
View ArticleEISAI TO INITIATE PHASE II CLINICAL STUDY OF DUAL OREXIN RECEPTOR ANTAGONIST...
(Source: Eisai Co Ltd) Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, 'Eisai') announced today the initiation of a Phase II clinical study of its internally-discovered oral dual orexin...
View ArticleNew data supporting gradual up-titration of ponesimod to mitigate first-dose...
(Source: Actelion Ltd) ALLSCHWIL, SWITZERLAND - 25 June 2015 - Actelion Ltd (SIX: ATLN) today announced that data supporting a gradual up-titration dose regimen of ponesimod will be presented at the...
View ArticleDesperately Seeking Shut-Eye
In the early 1970s, a colleague of Stanford University’s William Dement remarked on the resemblance of a narcolepsy patient’s symptoms to those of a recent canine patient he had read about. The...
View ArticleActelion announces changes to its executive team upon completion of the...
ALLSCHWIL/BASEL, SWITZERLAND- 14 June 2017 - Actelion Ltd (SIX: ATLN) today announced changes to its executive team that will take effect upon the settlement of the public tender offer by Johnson &...
View ArticleJohnson & Johnson to Acquire Actelion for $30 Billion With Spin-Out of New...
(Source: Janssen Pharmaceuticals Inc) Actelion Shareholders to Receive $280 Per Actelion Share in All-Cash Tender Offer to be Launched by Johnson & Johnson and One Share of New R&D Company for...
View ArticleCORRECTION: JOHNSON & JOHNSON TO ACQUIRE ACTELION FOR $30 BILLION WITH...
In the previous press release the companies omitted the cash amount with which R&D NewCo will launch. This has now been rectified and noted as CHF 1 billion. Actelion Shareholders to Receive $280...
View ArticleJOHNSON & JOHNSON TO ACQUIRE ACTELION FOR $30 BILLION WITH SPIN-OUT OF NEW...
For Immediate Release� Actelion Shareholders to Receive $280 Per Actelion Share in All-Cash Tender Offer to be Launched by Johnson & Johnson and One Share of New R&D Company for Each Actelion...
View ArticleCORRECTION: JOHNSON & JOHNSON TO ACQUIRE ACTELION FOR $30 BILLION WITH...
(Source: Actelion Ltd) In the previous press release the companies omitted the cash amount with which R&D NewCo will launch. This has now been rectified and noted as CHF 1 billion. Actelion...
View ArticleJOHNSON & JOHNSON TO ACQUIRE ACTELION FOR $30 BILLION WITH SPIN-OUT OF NEW...
(Source: Actelion Ltd) For Immediate Release Actelion Shareholders to Receive $280 Per Actelion Share in All-Cash Tender Offer to be Launched by Johnson & Johnson and One Share of New R&D...
View ArticleActelion emphasizes commitment to advance research and care in rare diseases...
(Source: Actelion Ltd) 'Patient Voice - Join us in making the voice of rare diseases heard.' This is the theme of Rare Disease Day 2016 - and a cause for Actelion to emphasize its long-term commitment...
View Article